Skip to main content
. 2021 Dec 14;12:7105. doi: 10.1038/s41467-021-27316-2

Fig. 1. Study flow diagram.

Fig. 1

Includes all screened and randomized participants. Participants who received dose 1 but not dose 2 continued to be evaluated for safety and immunogenicity.